Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $28.9 million.

  • Krystal Biotech's Shares Outstanding (Weighted Average) rose 123.11% to $28.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $28.9 million, marking a year-over-year increase of 123.11%. This contributed to the annual value of $28.9 million for FY2025, which is 123.11% up from last year.
  • As of Q4 2025, Krystal Biotech's Shares Outstanding (Weighted Average) stood at $28.9 million, which was up 123.11% from $29.0 million recorded in Q3 2025.
  • Krystal Biotech's 5-year Shares Outstanding (Weighted Average) high stood at $29.0 million for Q3 2025, and its period low was $21.3 million during Q1 2021.
  • In the last 5 years, Krystal Biotech's Shares Outstanding (Weighted Average) had a median value of $26.9 million in 2023 and averaged $26.4 million.
  • Per our database at Business Quant, Krystal Biotech's Shares Outstanding (Weighted Average) skyrocketed by 1816.62% in 2022 and then surged by 82.53% in 2025.
  • Krystal Biotech's Shares Outstanding (Weighted Average) (Quarter) stood at $22.2 million in 2021, then rose by 14.85% to $25.5 million in 2022, then increased by 6.52% to $27.2 million in 2023, then grew by 5.3% to $28.6 million in 2024, then increased by 1.23% to $28.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $28.9 million for Q4 2025, versus $29.0 million for Q3 2025 and $28.9 million for Q2 2025.